Renukaradhya Gourapura
· Professor and Director of Center Food Animal HealthOhio State University · Animal Sciences
Active 1996–2025
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Renukaradhya Gourapura, DVM, PhD, is a Professor and Director of the Center for Food Animal Health at The Ohio State University. He holds degrees from the Indian Institute of Science in Bangalore, including a PhD obtained in 2002, an MVSc (MS) from the University of Agricultural Sciences in Bangalore, and a BVSc (DVM) from the same university. His research focuses on mucosal immunology in food animals infected with infectious and zoonotic diseases, with particular attention to mucosal delivery of vaccines to improve cross-protective immunity against RNA viruses and mucosal pathogens. Dr. Gourapura's laboratory develops innovative biodegradable and biocompatible polymer-based nanoparticle vaccine delivery platforms aimed at efficiently targeting vaccine antigens to immune cells at mucosal sites. His work involves understanding immune correlates of protection and efficacy following viral or bacterial challenge infections in animals vaccinated via intranasal and oral routes. His research includes improving the efficacy of inactivated whole pathogen and subunit vaccines for influenza virus and porcine reproductive and respiratory syndrome virus, as well as evaluating immune modulators, bacterial-based and synthetic adjuvants, and different polymers-based vaccine carriers targeting toll-like receptors in mucosal immune sites of food animals and poultry. Currently, his lab investigates nanoparticle-based SARS-CoV-2 subunit vaccine candidates in ferret and pig models to determine…
Selected publications
Frontiers in Immunology · 2021-03-04 · 41 citations
articleOpen accessSenior authorCorrespondingParenteral administration of killed/inactivated swine influenza A virus (SwIAV) vaccine in weaned piglets provides variable levels of immunity due to the presence of preexisting virus specific maternal derived antibodies (MDA). To overcome the effect of MDA on SwIAV vaccine in piglets, we developed an intranasal deliverable killed SwIAV antigen (KAg) encapsulated chitosan nanoparticles called chitosan-based NPs encapsulating KAg (CS NPs-KAg) vaccine. Further, to target the candidate vaccine to d…
npj Vaccines · 2022-02-23 · 32 citations
articleOpen accessRecombinant protein approaches offer major promise for safe and effective vaccine prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent. In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humora…
Proceedings of the National Academy of Sciences · 2021-08-05 · 27 citations
articleOpen accessSignificance We report that suppression of the serine protease elastase reshapes innate responses induced by injected vaccines containing alum adjuvant. This reprogramming improves the induction of protective antibodies in the bloodstream and stimulates innate signals, which support the development of antibody responses in mucosal tissues. Our findings identify elastase as the innate regulator that blunts the adjuvant activity of alum. They also demonstrate that vaccination via mucosal routes is…
Scientific Reports · 2023-07-26 · 21 citations
articleOpen accessWe developed a novel intranasal SARS-CoV-2 subunit vaccine called NARUVAX-C19/Nano based on the spike protein receptor-binding domain (RBD) entrapped in mannose-conjugated chitosan nanoparticles (NP). A toll-like receptor 9 agonist, CpG55.2, was also added as an adjuvant to see if this would potentiate the cellular immune response to the NP vaccine. The NP vaccine was assessed for immunogenicity, protective efficacy, and ability to prevent virus transmission from vaccinated animals to naive cage…
Poultry Science · 2024-02-17 · 17 citations
articleOpen accessSenior authorCorrespondingNon-typhoidal Salmonella infection is a significant health and economic burden in poultry industry. Developing an oral vaccine to induce robust mucosal immunity in the intestines of birds, especially cross protection against different Salmonella serotypes is challenging. Therefore, a potent oral vaccine platform that can mitigate different serotypes of Salmonella is warranted for the poultry industry. We reported earlier that the Salmonella enteritidis (SE) immunogenic outer membrane proteins (O…
Similar researchers at Ohio State University
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Renukaradhya Gourapura
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup